Core Viewpoint - The financing activities of EasyBio (300942) indicate a positive sentiment among investors, with a net financing purchase of 2.15 million yuan on September 25, 2025, and a total net purchase of 3.28 million yuan over the last three trading days [1][4]. Financing Summary - On September 25, 2025, EasyBio had a financing balance of 125 million yuan, reflecting an increase of 1.74% from the previous day [4]. - The net financing purchases for the last few trading days are as follows: - September 25: 2.15 million yuan - September 24: 225,600 yuan - September 23: 906,300 yuan - September 22: 2.03 million yuan - September 19: 513,700 yuan [2][4]. - Over the last 20 trading days, there were 13 days with net financing purchases, indicating sustained investor interest [1]. Margin Trading Summary - On September 25, 2025, there were no shares sold on margin, but 1,300 shares were repaid, resulting in a net margin purchase of 1,300 shares and a remaining margin balance of 1,000 shares [3]. - The margin balance on September 25 was recorded at 10,600 yuan [3].

Group 1 - The core point of the news is that Yirui Biotech (300942) has seen a net financing inflow of 1.2464 million yuan on September 16, 2025, with a total financing balance of 12.4 million yuan, indicating a positive trend in investor interest [1][2][3] - Over the past three trading days, Yirui Biotech has accumulated a total net financing inflow of 8.5445 million yuan, suggesting a growing confidence among investors [1] - In the last 20 trading days, there have been 11 days with net financing inflows, reflecting a consistent demand for the company's shares [1] Group 2 - The financing balance on September 16, 2025, increased by 1.02% compared to the previous day, indicating a slight upward trend in the overall financing activity [3] - The financing balance on September 15, 2025, was 1.23 billion yuan, which also showed a 1.54% increase from the previous day [3] - The financing net inflow on September 12, 2025, was the highest in the observed period at 5.4529 million yuan, highlighting a peak in investor activity [2][3]

Group 1 - The company, Easybio (300942), announced the election of Mr. Mo Qiuhua as the employee representative director of the third board of directors during the employee representative meeting held on September 15, 2025 [1]

深圳市易瑞生物技术股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-066 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 三、备查文件 1 特此公告。 深圳市易瑞生物技术股份有限公司 董事会 一、非独立董事辞职的情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）董事会于近日收到 公司非独立董事陈智英女士递交的书面辞职报告。因公司治理结构调整，陈智英 女士申请辞去公司第三届非独立董事职务及战略委员会委员职务，辞职后，陈智 英女士将继续担任公司副总经理职务。陈智英女士原定任期至第三届董事会届满 之日，即 2027 年 3 月 31 日止。 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》《公司章程》等有关规定，陈智英女士的辞职不会导致公司 董事会成员低于法定最低人数，不会影响公司董事会的正常运作，其辞职报告自 送达董事会之日起生效 ...

2025年第二次临时股东大会法律意见书 致：深圳市易瑞生物技术股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受深圳市易瑞生物技术股份有 限公司（以下简称"公司"）的委托，指派张韵雯律师、李德齐律师（以下简称"本 所律师"）出席公司2025年第二次临时股东大会（以下简称"本次股东大会"或"本 次会议"），对本次股东大会的合法性进行见证。本所律师根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法律、法规和规范 性文件以及《深圳市易瑞生物技术股份有限公司章程》（以下简称"《公司章程》"） 的规定，就公司本次股东大会的召集、召开程序、出席会议人员的资格、召集人的资 格、表决程序和表决结果等有关事宜出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席会议人 员资格、召集人的资格、表决程序以及表决结果是否符合相关法律、法规、其他规范 性文件及《公司章程》的规定发表意见，不对会议审议的议案内容以及这些议案所表 述的事实或数据的真实性及准确性发表意见。 按照律师行业公认的业务标准、道德规范和勤勉尽责精神，本所律师对本次股东 大会的相关资料和事实进行 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-065 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议的召开情况 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年9月15日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票的时间为2025年9月15日9:15至15:00。 2、现场会议地点：深圳市宝安区航城街道三围社区运昌路289号易瑞生物产 业园2栋公司会议室 3、会议召开方式：现场表决与网络投票相结合的方式 4、会议召集人：公司董事会 5、会议主持人：董事长肖昭理先生 6、会议召开 ...

Core Viewpoint - Erye Biological (300942.SZ) announced a significant reduction in shareholding by its controlling shareholder Erye (Hainan) Venture Capital Co., Ltd. and actual controller Zhu Hai, indicating a strategic shift in ownership structure [1][2]. Summary by Relevant Sections Shareholding Changes - From September 2 to September 5, 2025, Erye Venture Capital and Zhu Hai collectively reduced their holdings in Erye Biological by 4,167,032 shares, representing 1.0287% of the total share capital [1]. - Post-reduction, the total shares held by Erye Venture Capital and Zhu Hai decreased from 238,293,404 shares to 234,126,372 shares, reducing their ownership percentage from 58.8279% to 57.7992% [1]. Total Reduction Overview - As of September 5, 2025, the total shares reduced by Erye Venture Capital and Zhu Hai amounted to 11,052,532 shares, accounting for 2.7286% of the total share capital [1]. - The reduction plan has been fully implemented [1]. Transaction Details - Erye Venture Capital sold 3,531,208 shares through block trading at an average price of 10.66 CNY per share between September 1 and September 5, 2025 [2]. - Zhu Hai sold 3,626,200 shares via centralized bidding at an average price of 12.96 CNY per share from August 6 to September 5, 2025 [2]. - Additionally, Zhu Hai sold 3,895,124 shares through block trading at an average price of 10.37 CNY per share from July 28 to September 4, 2025 [2]. - The total amount from these share reductions was approximately 125 million CNY [2].

关于控股股东、实际控制人及其一致行动人权益变动触及 1%整 数倍暨减持计划实施完毕的公告 公司控股股东、实际控制人及其一致行动人保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-064 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 ¹公司发行的"易瑞转债"已于 2024 年 2 月 26 日开始转股，截至 2025 年 6 月 30 日，公司总股本为 401,317,665 股。 1 ----------------------------------- 公司于近日收到控股股东易瑞创投、实际控制人朱海先生出具的《关于减持 股份比例触及 1%整数倍暨减持计划实施完毕的告知函》，获悉自 2025 年 9 月 2 日至 2025 年 9 月 5 日，易瑞创投、朱海先生通过集中竞价及大宗交易方式合计 减持公司股份 4,167,032 股，占公司目前总股本 ...

Group 1 - The company has established a food safety testing business in schools, providing testing reagents and setting up rapid testing laboratories to monitor the cleanliness of food ingredients and utensils in school canteens [1] - The company has collaborated with several universities, including Jiangxi University of Science and Technology, China Agricultural University, and Tsinghua University, to enhance food safety measures [1] - There is an inquiry regarding the company's expansion into the university market, specifically about whether Nanjing University of Chinese Medicine is using the company's testing equipment [2]

证券代码：300942 证券简称：易瑞生物 公告编号：2025-063 债券代码：123220 债券简称：易瑞转债 深圳市易瑞生物技术股份有限公司 关于控股股东、实际控制人及其一致行动人权益变动 触及 1%整数倍的提示性公告 公司控股股东、实际控制人及其一致行动人保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 | 本次权益变动情况 | | --- | | 1、基本情况 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | 1 | | | 易瑞创投 | | | | 住所 | | | | 海南省澄迈县****** | | | | 信息披露义务人 | 2 | | | 朱海 | | | | 住所 | | | | 广东省深圳市宝安区****** | | | | 信息披露义务人 | 3 | | | 深圳易达瑞管理咨询合伙企业（有限合伙） | | | | 住所 | | | | 广东省深圳市宝安区****** | | | | 信息披露义务 ...